Late phase drug development is growing at around 20% annually, exceeding the growth rate of Phase II and III Trials. In excess of $12 billion is currently being spent on Phase IIIb/IV studies as public concerns on the safety of approved drugs prevail together with the need to evaluate real world safety and effectiveness of marketed drugs. More than ever before there is the urgent need to detect, quantify and communicate patient risk with speed and efficiency.
As a result, Health Network Communications is delighted to announce the first ever strategic forum in the US addressing the major challenges in conducting strategic and compliant late stage studies.